Pharma Focus Asia

BiondVax Pharmaceuticals Signs Exclusive Licence Agreement to Develop and Commercialise Novel Anti-IL-17 Antibody

Monday, June 05, 2023

BiondVax Pharmaceuticals announced that it has signed an exclusive worldwide licence agreement to develop and commercialise VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for various indications, starting with psoriasis and psoriatic arthritis. This collaboration involves the Max Planck Society and the University Medical Centre Gottingen (UMG).

Indeed, the licence agreement between BiondVax Pharmaceuticals and Max Planck for the IL-17 NanoAb represents an exciting opportunity for the development of a unique treatment for psoriasis and other autoimmune diseases. This collaboration serves as a validation of the productive relationship between BiondVax, Max Planck, and UMG, highlighting the potential for further significant developments in the future.

The BiondVax-MPG-UMG research collaboration agreement outlines rigorous criteria that NanoAb candidates must meet before being in-licenced by BiondVax. These criteria include factors such as binding affinity, neutralisation of the target, and other relevant attributes. By setting high standards for the NanoAb candidates, the collaboration aims to ensure the development of effective and promising treatments.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024